Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
Completed
- Conditions
- Left Ventricular Hypertrophy
- Registration Number
- NCT01198899
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 540
Inclusion Criteria
- All patients over 18 years undergoing a routine echocardiography in the participating hospitals
- Both genders will be considered.
- Patients can be included if on 2D echocardiography the maximal septal wall thickness > 13 mm and/or the posterior wall thickness > 13 mm. The limit for inclusion is kept relatively low to detect early forms of Fabry cardiomyopathy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography At baseline T0 patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
AZ Imelda
🇧🇪Bonheiden, Belgium
AZ Sint-Blasius
🇧🇪Dendermonde, Belgium
AZ Sint-Lucas
🇧🇪Gent, Belgium
Maria Middelares
🇧🇪Gent, Belgium
University Hospital Ghent
🇧🇪Ghent, Belgium
Jan Yperman Ziekenhuis
🇧🇪Ieper, Belgium
AZ Oostkust
🇧🇪Knokke-Heist, Belgium
ZOL
🇧🇪Limburg, Belgium
AZ Zusters van Barmhartigheid
🇧🇪Ronse, Belgium
AZ Imelda🇧🇪Bonheiden, Belgium